May 30, 2017 08:15 AM EDT

Bristol-Myers Squibb adds to its roster of checkpoint combo studies, partnering with Array and Advaxis

John Carroll

Editor & Founder

The parade of new immuno-oncology partnerships continued Tuesday morning with two new alliances on the checkpoint front from Bristol-Myers Squibb $BMY.

Deal #1: Bristol-Myers is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol-Myers Squibb adds to its roster of checkpoint combo studies, partnering with Array and Advaxis

John Carroll

Editor & Founder

Sign up to read this article for free.

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Bris­tol-My­ers Squibb adds to its ros­ter of check­point com­bo stud­ies, part­ner­ing with Ar­ray and Ad­vax­is

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bristol-Myers Squibb adds to its roster of checkpoint combo studies, partnering with Array and Advaxis

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy